CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
September 11, 2023 06:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and...
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
September 06, 2023 16:05 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2023 16:29 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
August 10, 2023 16:04 ET
|
CymaBay Therapeutics, Inc.
Top-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET ...
CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
August 03, 2023 16:05 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 16:04 ET
|
CymaBay Therapeutics, Inc.
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of...
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
May 10, 2023 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Names Harish Shantharam Chief Financial Officer
May 09, 2023 08:00 ET
|
CymaBay Therapeutics, Inc.
Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK,...
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
April 21, 2023 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 17, 2023 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...